Cargando…
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology, and the limited available therapeutic options for this disease, are frustrating to both clinicians and patients. However, recent advances in the understanding of disease mechanisms have given rise to numerous stu...
Autores principales: | Wiesik-Szewczyk, E, Olesinska, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460634/ https://www.ncbi.nlm.nih.gov/pubmed/23055692 http://dx.doi.org/10.2147/BTT.S25407 |
Ejemplares similares
-
Rituximab therapy for juvenile-onset systemic lupus erythematosus
por: Nwobi, Obioma, et al.
Publicado: (2007) -
Quality of life in systemic lupus erythematosus and its measurement
por: Olesińska, Marzena, et al.
Publicado: (2018) -
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
por: Wise, Leanna M., et al.
Publicado: (2020) -
Immunopathogenesis and Novel Therapeutics Strategies of Systemic Lupus Erythematosus
por: Kotyla, Przemysław, et al.
Publicado: (2023) -
Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Patients with Systemic Lupus Erythematosus
por: Atay, Didem, et al.
Publicado: (2012)